Emergent Biosolutions (EBS)
NYSE:EBS
Earnings Data
Report Date
May 13, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.25Last Year’s EPS
0.71Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted substantial operational and financial progress — notable margin expansion, strong adjusted EBITDA growth to $205M (+12% YoY), significant deleveraging (net leverage improved to 1.9x), improved liquidity (cash $205M, total liquidity $305M) and international contract momentum (Canada CAD 140M, 34% of MCM revenue international). Management also emphasized product innovation and real-world impact for NARCAN. However, revenue declined versus 2024 (partly due to the absence of prior one-time items), naloxone demand faced temporary softness from a U.S. government shutdown and regional pricing/county effects, U.S. government orders moderated to a new baseline, and 2026 guidance implies lower adjusted EBITDA and an expected GAAP net loss. On balance, the positive operational execution, margin and cash-flow improvements and deleveraging materially outweigh the near-term topline and guidance headwinds.Company Guidance
Adjusted EBITDA Growth and Profitability Expansion
Adjusted EBITDA of $205 million in 2025, up $22 million or 12% year-over-year; expanded adjusted EBITDA margin and overall profitability, with adjusted EBITDA landing at the high end of guidance for the year.
Material Gross Margin Improvement
Adjusted gross margin expanded meaningfully — +900 basis points year-over-year for full year 2025; Q4 adjusted gross margin improved 300 basis points to 43%, driven by product mix and operational efficiencies.
Significant Operating Expense Reductions
Operating expenses decreased by $140 million versus 2024 (a ~37% reduction for the year); Q4 operating expenses were down ~10% year-over-year, underscoring disciplined cost management.
Enhanced Liquidity and Deleveraging
Year-end cash of $205 million and total liquidity of $305 million (including $100 million undrawn revolver); operating cash flow grew 190% to $171 million; net leverage improved to 1.9x from 3.3x at year-end 2024 following $110 million of gross debt paydown (including a $100 million voluntary term-loan prepayment).
Shareholder Returns and Capital Allocation
Repurchased 3.1 million shares in 2025 and announced a new $50 million buyback authorization through March 31, 2027; also repurchased $10.3 million principal amount of unsecured bonds for $8.7 million cash.
Strength in International MCM and Large Contract Wins
International momentum grew with medical countermeasure (MCM) international sales representing 34% of full-year MCM revenue; executed new multiyear agreements with Canada valued at CAD 140 million and made deliveries to over 20 countries.
Naloxone Product Innovations and Real-World Impact
Received FDA approval for 6-count and 24-count multi-use configurations of NARCAN; launched a compact carrying case informed by a consumer survey showing 74% overall preference (81% among college students); cited peer-reviewed analysis indicating naloxone administration in New York State saved >6,500 lives and >200,000 years of life (2023–Mar 2025).
2026 Guidance Providing Clear Financial Targets
Initial 2026 outlook: total revenues of $720–760 million, adjusted gross margin 45–47%, adjusted EBITDA $135–155 million, adjusted net income $25–45 million; Q1 revenue guide $135–155 million and first-half revenues expected to be ~40% of full-year total.
EBS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EBS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $11.10 | $8.15 | -26.58% |
Oct 29, 2025 | $9.40 | $12.84 | +36.60% |
Aug 06, 2025 | $6.03 | $8.24 | +36.65% |
May 07, 2025 | $4.74 | $6.36 | +34.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Emergent Biosolutions (EBS) report earnings?
Emergent Biosolutions (EBS) is schdueled to report earning on May 13, 2026, TBA (Confirmed).
What is Emergent Biosolutions (EBS) earnings time?
Emergent Biosolutions (EBS) earnings time is at May 13, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EBS EPS forecast?
EBS EPS forecast for the fiscal quarter 2026 (Q1) is -0.25.